HopeStage
Back to all studies
Enrolling By InvitationNCT07680959

Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia

Device studyAges 18–65Taiwan
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
TaipeiSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 6, 2024
Recruitment status
Enrolling By Invitation
Enrollment listed in the registry
100
Sponsor
Tri-Service General Hospital (TSGH)
Sponsor type
Hospital / academic medical center
Study type
Device
Intervention type
Device
Locations
Taiwan
Age range
From 18 Years to 65 Years
Official registry ID
NCT07680959
Official title
Show the full official title

The Efficacy of Combined HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia

Recruitment & locations

By invitation

Taipei

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tri-Service General Hospital (TSGH), a hospital or academic medical center.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as enrolling by invitation.

Want to explore more studies?

Explore studies